BioCopy AG

#JobOpportunity #IT BioCopy sucht zum nächstmöglichen Zeitpunkt eine/n IT ADMINISTRATOR/IN Werde Teil unseres innovativen Teams! 🙂   Aufgabenprofil ➡️  Support im Soft- und Hardwarebereich in einem Windows, Linux (Ubuntu) und macOS Umfeld  ➡️ Fehlerbehebung bei System-, Netzwerk- und Softwareproblemen  ➡️ Kleinere Anpassungen sowie Problembehebung (software- und hardwareseitig) an Serversystemen  ➡️ Installation und Wartung der Clienthardware In-House  ➡️ Unterstützung der gesamten Netzwerkinfrastruktur von Ubiquiti/UniFi  Wartung der Windows Server 2019- 2022 (On Premise wie Cloud) und macOS X Server 10.13 -15  ➡️ Überwachung sowie Verwaltung unserer Managed-Service-Plattformen inkl. selbstständiger Bearbeitung von erkannten Problemen (bspw. ESET, Acronis) Zur Vollen Stellenausschreibung geht's hier: https://lnkd.in/eZcKNx85 Wir freuen uns auf Bewerbungen an career@biocopy.com an.

After announcing the collaboration of #YUMAB and #BioCopy, first proof of concept data on TCR-like antibodies were presented on this year #FOB in Basel.  These antibodies show superior target specificity and sensitivity as compared to established reference antibodies. Together, we will expand our antibody discovery pipeline to novel TCRm targets for the development of novel therapeutics with improved specificity profiles.  Stay tuned for further news 😉. #BioCopy #YUMAB #TCRm #Collaboration #Antibody

Great to have you on board as our Chief People Officer Maike July!

Wir sind auf dem richtigen Weg mit Daten-gestützten AI-Lösungen in der Medikamentenentwicklung. Die nächsten Jahre werden spannend (bleiben), wenn wir den Einfluß, den ChatGPT und andere Plattformen vorlegen, auch in anderen Industrien und vor allem in der Medizinischen Forschung sehen werden.

🎉 We celebrate and humbly congratulate this year’s #NobelPrize winners in Chemistry, David Baker, Demis Hassabis, and John Jumper, for their outstanding achievement! 🏆 Their work brilliantly showcases the incredible value AI brings to science, particularly in predicting complex 3D structures of proteins. 🧬✨ This is the R&D world, we live in: not only does the Laureates’ work enhance our understanding of protein functions, it helps us SPEED UP the development of innovative biological drugs targeting diseases once thought untreatable. 💊🔬 At BioCopy, we’re proud to leverage our own AI models to develop drugs aimed at challenging #pHLA targets. This crucial work wouldn’t be possible without the foundational research conducted by this year’s Nobel Laureates. Thanks to these innovations, we’re developing new therapeutics for cancer types that previously had no treatment options. 💡🔝 #AIinScience #Innovation #DrugDevelopment #CancerResearch

🚀 In Pursuit of the Holy Grail in Biotherapeutics Innovation! 🚀 BioCopy is proud to share that Matthias Wiedenfels, recently had the honor of being interviewed by Jutta Mutschler, editor in chief of Market Access and Health Policy. In their engaging discussion, Matthias delves into the groundbreaking advancements in the discovery and development of next-generation #biotherapeutics. 🌟 Matthias shares his expertise and vision for the future of biotech R&D, highlighting our company's commitment to discovering the "holy grail" of next-generation biotherapeutics. Their conversation, published in the current issue of Market Access and Health Policy, is a testament to BioCopy's commitment to pioneering and changing the landscape of healthcare and the pharmaceutical industry. 👉 Check out the full interview here: https://lnkd.in/gY47V6PX Join us in celebrating this remarkable achievement and supporting the incredible work being done to advance biotherapeutics. We are immensely proud of Matthias and our entire team for their relentless pursuit of excellence and innovation. 🌐👏 #LifeScience #Innovation #pharma #oncology

Like Lock and Key or in other words: the perfect match! We joined forces! Together we're pushing push the boundaries of biopharmaceutical innovation! 🚀

🚀 Data match made in AI heaven 😇 We are thrilled to announce that we are now working with Genedata to power our multi-specific antibody discovery efforts with cutting-edge AI technology! 🎉 By integrating Genedata's leading enterprise software solution for biopharmaceutical R&D, we're taking a major leap towards revolutionizing the engineering of next-generation cancer therapeutics. 🧬💡 "Genedata serves as our data backbone, ensuring seamless analysis across all projects and groups, which accelerates our cancer drug development process," said Joerg Birkenfeld, Ph.D., CSO of BioCopy. "Our automated engineering lab generates vast amounts of complex data, and Genedata structures this information into high-quality, contextualized insights that feed into our AI platform." This collaboration marks a pivotal moment in our journey to develop safe and effective cancer therapeutics. We're more committed than ever to leveraging advanced technology and bring hope and healing to patients worldwide. Stay tuned for more updates as we continue to push the boundaries of biopharmaceutical innovation! 💪🔬✨ https://lnkd.in/gcv5-D8w #cancerdrugs #Biotechnology #datascience #AIdriven #Innovation

🎉We are shaping the future of novel cancer therapies with scientific ingenuity and high-quality data! 🌟🔬 The integration of advanced technologies is pivotal in transforming scientific discovery into life-saving cancer drugs. 🚀 BioCopy is at the forefront of developing next-generation #biopharmaceutical drug candidates for intracellular cancer targets. Our greatest asset is our wealth of proprietary biological data, a treasure trove which is constantly growing. As Joerg Birkenfeld, our CSO, emphasizes, "At BioCopy, we're not just transforming the drug development process; we're redefining it. With our cutting-edge technologies we leverage the power of AI and automation and streamline processes to identify promising candidates and expedite #drugdevelopment with unparalleled efficiency." Read more in Jörg's latest article, published in Pharma Focus Europe. Namir Hassan, Martin Klatt, Ivan Kugener, MD, Rainer Boehm 👇 starting on page 22. 😉 #drugdiscovery #Immunooncology #automation #datascience

👍 Unser CEO Matthias Wiedenfels zu Gast bei Wirtschaft mit Annette Weisbach. Die BioCopy Vision auf den Punkt gebracht. Reinhören lohnt sich! 🔊